Compare Gilead Sciences, Inc. (GILD) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Johnson & Johnson — how do they compare? Gilead Sciences, Inc. trades at $135 (market cap $164.99B), while Johnson & Johnson trades at $259 (market cap $630.94B). The key difference: Johnson & Johnson is far larger — about 3.8× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.47%). Which is the better fit depends on your goals.
| GILD | JNJ | |
|---|---|---|
Market Cap | $164.99B | $630.94B |
Sector | Health | Health |
52-Week High | $155.80 | $267.24 |
52-Week Low | $110.56 | $172.78 |
Enterprise Value | $188.06B | $659.21B |
Dividend Yield | 2.47% | 2.05% |
Volume | — | 6,156,228 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
